Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNotes PayablesOperating LeasesOther Non-Current AssetsPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Iovance Biotherapeutics (IOVA) Total Current Liabilities: 2010-2025

Historic Total Current Liabilities for Iovance Biotherapeutics (IOVA) over the last 8 years, with Sep 2025 value amounting to $125.8 million.

  • Iovance Biotherapeutics' Total Current Liabilities was N/A to $125.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $125.8 million, marking a year-over-year change of. This contributed to the annual value of $122.3 million for FY2024, which is 10.91% up from last year.
  • Latest data reveals that Iovance Biotherapeutics reported Total Current Liabilities of $125.8 million as of Q3 2025, which was down 2.61% from $129.2 million recorded in Q2 2025.
  • In the past 5 years, Iovance Biotherapeutics' Total Current Liabilities ranged from a high of $129.2 million in Q2 2025 and a low of $83.2 million during Q1 2024.
  • For the 3-year period, Iovance Biotherapeutics' Total Current Liabilities averaged around $106.7 million, with its median value being $110.3 million (2023).
  • As far as peak fluctuations go, Iovance Biotherapeutics' Total Current Liabilities dropped by 4.65% in 2024, and later surged by 47.44% in 2025.
  • Iovance Biotherapeutics' Total Current Liabilities (Quarterly) stood at $110.3 million in 2023, then increased by 10.91% to $122.3 million in 2024, then surged by 47.44% to $125.8 million in 2025.
  • Its Total Current Liabilities stands at $125.8 million for Q3 2025, versus $129.2 million for Q2 2025 and $122.7 million for Q1 2025.